vs
Side-by-side financial comparison of Inuvo, Inc. (INUV) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $14.3M, roughly 2.0× Inuvo, Inc.). Inuvo, Inc. runs the higher net margin — -4.2% vs -147.1%, a 143.0% gap on every dollar of revenue. On growth, Inuvo, Inc. posted the faster year-over-year revenue change (-45.6% vs -67.6%).
Inuvo, Inc. is a digital marketing technology firm that develops AI-powered advertising solutions. It offers intent-based audience targeting, performance marketing, and brand awareness services for retail, finance, and consumer goods clients, mainly operating across the North American market.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
INUV vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.3M | $28.1M |
| Net Profit | $-593.9K | $-41.3M |
| Gross Margin | 66.4% | — |
| Operating Margin | -8.5% | -147.6% |
| Net Margin | -4.2% | -147.1% |
| Revenue YoY | -45.6% | -67.6% |
| Net Profit YoY | -520.2% | -182.8% |
| EPS (diluted) | — | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $14.3M | $28.1M | ||
| Q3 25 | $22.6M | $32.5M | ||
| Q2 25 | $22.7M | $15.7M | ||
| Q1 25 | $26.7M | $8.0M | ||
| Q4 24 | $26.2M | $86.6M | ||
| Q3 24 | $22.4M | $2.1M | ||
| Q2 24 | $18.2M | $500.0K | ||
| Q1 24 | $17.0M | $0 |
| Q4 25 | $-593.9K | $-41.3M | ||
| Q3 25 | $-1.7M | $-51.2M | ||
| Q2 25 | $-1.5M | $-44.9M | ||
| Q1 25 | $-1.3M | $-33.9M | ||
| Q4 24 | $141.3K | $49.9M | ||
| Q3 24 | $-2.0M | $-19.1M | ||
| Q2 24 | $-1.7M | $-12.5M | ||
| Q1 24 | $-2.1M | $-10.3M |
| Q4 25 | 66.4% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 75.4% | — | ||
| Q1 25 | 79.0% | — | ||
| Q4 24 | 83.1% | — | ||
| Q3 24 | 88.4% | — | ||
| Q2 24 | 84.0% | — | ||
| Q1 24 | 87.7% | — |
| Q4 25 | -8.5% | -147.6% | ||
| Q3 25 | -7.4% | -163.7% | ||
| Q2 25 | -9.0% | -302.9% | ||
| Q1 25 | -6.6% | -466.3% | ||
| Q4 24 | 0.8% | 54.5% | ||
| Q3 24 | -8.7% | -1051.6% | ||
| Q2 24 | -9.3% | -3068.0% | ||
| Q1 24 | -12.3% | — |
| Q4 25 | -4.2% | -147.1% | ||
| Q3 25 | -7.7% | -157.4% | ||
| Q2 25 | -6.6% | -285.6% | ||
| Q1 25 | -4.7% | -425.7% | ||
| Q4 24 | 0.5% | 57.7% | ||
| Q3 24 | -9.1% | -925.0% | ||
| Q2 24 | -9.6% | -2503.2% | ||
| Q1 24 | -12.4% | — |
| Q4 25 | — | $-0.41 | ||
| Q3 25 | $-0.12 | $-0.52 | ||
| Q2 25 | — | $-0.46 | ||
| Q1 25 | $-0.01 | $-0.35 | ||
| Q4 24 | $0.14 | $0.52 | ||
| Q3 24 | $-0.15 | $-0.20 | ||
| Q2 24 | $-0.01 | $-0.13 | ||
| Q1 24 | $-0.02 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $10.0M | $114.3M |
| Total Assets | $24.9M | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | $2.0M | $218.7M | ||
| Q1 24 | $2.0M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $10.0M | $114.3M | ||
| Q3 25 | $10.4M | $147.7M | ||
| Q2 25 | $12.1M | $192.3M | ||
| Q1 25 | $13.4M | $229.0M | ||
| Q4 24 | $13.5M | $256.8M | ||
| Q3 24 | $12.4M | $201.0M | ||
| Q2 24 | $13.5M | $215.2M | ||
| Q1 24 | $15.1M | $223.9M |
| Q4 25 | $24.9M | $327.7M | ||
| Q3 25 | $29.9M | $372.8M | ||
| Q2 25 | $28.7M | $313.5M | ||
| Q1 25 | $31.7M | $327.3M | ||
| Q4 24 | $32.2M | $351.2M | ||
| Q3 24 | $29.0M | $217.6M | ||
| Q2 24 | $28.5M | $222.0M | ||
| Q1 24 | $29.8M | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $21.0K | $-43.5M |
| Free Cash FlowOCF − Capex | $-339.9K | — |
| FCF MarginFCF / Revenue | -2.4% | — |
| Capex IntensityCapex / Revenue | 2.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-3.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $21.0K | $-43.5M | ||
| Q3 25 | $-1.6M | $-47.0M | ||
| Q2 25 | $143.7K | $-39.6M | ||
| Q1 25 | $-366.9K | $-40.7M | ||
| Q4 24 | $329.9K | $42.0M | ||
| Q3 24 | $1.1M | $-14.5M | ||
| Q2 24 | $195.4K | $-7.3M | ||
| Q1 24 | $-1.4M | $-6.7M |
| Q4 25 | $-339.9K | — | ||
| Q3 25 | $-2.0M | $-47.2M | ||
| Q2 25 | $-263.1K | $-39.6M | ||
| Q1 25 | $-818.6K | $-40.8M | ||
| Q4 24 | $-117.7K | $41.7M | ||
| Q3 24 | $584.0K | $-14.6M | ||
| Q2 24 | $-266.3K | $-7.3M | ||
| Q1 24 | $-1.8M | $-6.8M |
| Q4 25 | -2.4% | — | ||
| Q3 25 | -8.7% | -145.4% | ||
| Q2 25 | -1.2% | -252.2% | ||
| Q1 25 | -3.1% | -512.1% | ||
| Q4 24 | -0.4% | 48.2% | ||
| Q3 24 | 2.6% | -706.3% | ||
| Q2 24 | -1.5% | -1463.4% | ||
| Q1 24 | -10.7% | — |
| Q4 25 | 2.5% | 0.0% | ||
| Q3 25 | 1.7% | 0.6% | ||
| Q2 25 | 1.8% | 0.3% | ||
| Q1 25 | 1.7% | 1.1% | ||
| Q4 24 | 1.7% | 0.3% | ||
| Q3 24 | 2.1% | 6.8% | ||
| Q2 24 | 2.5% | 7.6% | ||
| Q1 24 | 2.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.33× | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INUV
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
